Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Invest New Drugs. 2017 Nov 21;36(4):638–646. doi: 10.1007/s10637-017-0534-0

Figure 2. Overall survival (OS) in patients treated on immunotherapy-based regimens by incidence of grade 3 or 4 irAEs.

Figure 2

The estimates of median OS was longer in patients who developed grade ≥3 irAEs (15 months) compared to patients who did not (8 months); p=0.10